Furthermore, Nrf2 activators increase bacterial phagocytosis and killing in COPD macrophages, suggesting that this might be a useful pharmacological approach for COPD-associated defects in bacterial clearance (Bewley et al. 2018). This evidence concerns the gene NFE2L2 and chronic obstructive pulmonary disease.